ALIZE PHARMA II Pegcrisantaspase Program
Prior to its acquisition by a subsidiary of Jazz Pharmaceuticals plc in March 2016, Alizé Pharma II SAS was focused on the development of pegcrisantaspase (ASPAREC®), a new pegylated recombinant L-asparaginase in onco-hematological rare diseases.
- Allas S et al. “Pharmacokinetics and pharmacodynamics in mice of a PEGylated recombinant Erwinia chrysanthemi-derived L-asparaginase”. Abstract #2033. 51st ASH annual meeting, December 5-8, 2009 (New-Orleans, LA). 2009.
- Allas S et al. “Immunogenicity profile in mice of a PEGylated recombinant Erwinia chrysanthemi-derived L-asparaginase”. Abstract #2034. 51st ASH annual meeting, December 5-8, 2009 (New-Orleans, LA). 2009.
- Chien WW, Allas S, Rachinel N, Sahakian P, Julien M, Le Beux C, Lacroix CE, Abribat T, Salles G. Pharmacology, immunogenicity and efficacy of novel pegylated recombinant Erwinia Chrysanthemi-derived L-asparaginase. Invest New Drugs. 2014 Oct;32(5):795-805.
- Chien WW, Le Beux C, Rachinel N, Julien M, Lacroix CE, Allas S, Sahakian P, Cornut-Thibaut A, Lionnard L, Kucharczak J, Aouacheria A, Abribat T, Salles G. Differential mechanisms of asparaginase resistance in B-type acute lymphoblastic leukemia and malignant natural killer cell lines. Sci Rep. 2015 Jan 28;5:8068.